Get started:
[idea]
You've got a bold venture idea

Got a groundbreaking idea for your next venture? Join Achmea Impact Ventures and build your startup from the ground up with expert support and funding.

[startup]
You have a startup and want to scale

Ready to scale your startup? We invest in high-potential businesses with >€50k ARR, providing funding, expert advice and a strong network

[scaleup]
You are part of our portfolio

We invest in our own portfolio companies to help them scale with funding, strategy, and Achmea’s network.

[idea]
You've got a bold venture idea

Got a groundbreaking idea for your next venture? Join Achmea Impact Ventures and build your startup from the ground up with expert support and funding.

[startup]
You have a startup and want to scale

Ready to scale your startup? We invest in high-potential businesses with >€50k ARR, providing funding, expert advice and a strong network

[scaleup]
You are part of our portfolio

We invest in our own portfolio companies to help them scale with funding, strategy, and Achmea’s network.

Qurin

“

Qurin is developing a test that detects cancer through urine instead of an invasive tissue biopsy, currently focusing on the early detection of bladder cancer.

”
[Domain]
Healthcare
[Stage]
Scale up
[Founders]
Prof. Dr. Bob Pinedo
[Acceleration]
10x
Who is Qurin?

Qurin (Qurin Diagnostics) is a biotech R&D company based at Leiden Bio Science Park, with, among other things, a USD 2.3M subcontract within ARPA-H’s POSEIDON programme. Whereas cancer diagnostics typically rely on invasive tissue biopsies that provide only a local ‘snapshot’, Qurin is developing a platform for urine-based ‘liquid biopsy’ diagnostics (Qatra + Qumbra), currently focused on the early detection and monitoring of bladder cancer.